Eke Ahizechukwu C, Chalaan Tina, Shukr Ghadear, Eleje George U, Okafor Charles I
Department of Obstetrics and Gynecology, Michigan State University/Sparrow Hospital, Lansing, MI, USA.
College of Human Medicine, Michigan State University, Lansing, MI, USA.
Int J Gynaecol Obstet. 2016 Jan;132(1):11-6. doi: 10.1016/j.ijgo.2015.06.058. Epub 2015 Oct 18.
The use of progestogens for maintenance tocolysis remains controversial, with randomized controlled trials having conflicting results on their efficacy.
To evaluate the use of progestational agents for maintenance tocolysis after preterm labor in a systematic review of randomized controlled trials.
Electronic databases were searched for reports published before December 2014. Keywords included "tocolysis," "progesterone," "preterm labor," "17-alpha-hydroxyprogesterone," and "vaginal progesterone."
Only randomized controlled trials involving progestational agents for maintenance tocolysis were included.
Outcomes were analyzed on an intent-to-treat basis and meta-analysis was performed where appropriate. Relative risks and mean differences with 95% confidence intervals were calculated.
Four studies (362 women) were included. There were no significant differences between progestational agents and placebo/no treatment in terms of delivery before 34weeks or before 37weeks of pregnancy, time from randomization to delivery, and respiratory distress syndrome. Progestogens were associated with an increase in the neonatal birth weight (mean difference 203.32g, 95% confidence interval 110.85-295.80; P=0.032).
The current evidence does not support the routine use of progestational agents for maintenance tocolysis after an episode of preterm labor.
使用孕激素进行维持性保胎治疗仍存在争议,随机对照试验对其疗效的结果相互矛盾。
在一项随机对照试验的系统评价中,评估孕激素制剂在早产后宫缩抑制维持治疗中的应用。
检索电子数据库中2014年12月之前发表的报告。关键词包括“宫缩抑制”“孕酮”“早产”“17-α-羟孕酮”和“阴道用孕酮”。
仅纳入涉及孕激素制剂用于维持性宫缩抑制的随机对照试验。
按意向性分析原则分析结果,并在适当情况下进行荟萃分析。计算相对风险和95%置信区间的均值差。
纳入4项研究(362名女性)。在妊娠34周前或37周前分娩、随机分组至分娩的时间以及呼吸窘迫综合征方面,孕激素制剂与安慰剂/未治疗之间无显著差异。孕激素与新生儿出生体重增加相关(均值差203.32g,95%置信区间110.85 - 295.80;P = 0.032)。
目前的证据不支持在早产发作后常规使用孕激素制剂进行维持性宫缩抑制治疗。